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Mitochondrial-Mimicking Monolayers 
(Under the direction of Dr. Saame Raza Shaikh) 
 
Cardiolipin (CL) is a mitochondrial phospholipid that plays a fundamental role in 
maintaining inner membrane (IMM) structure-function. In several metabolic diseases, CL is 
shown to undergo alterations in content and acyl chain composition, though there is still debate 
as to which alteration is the major contributor to pathology. Therefore, this study distinguished 
the roles of CL content and acyl chain composition on influencing IMM biophysical 
organization. We utilized Langmuir monolayers to study lipid packing properties of CL, from 
which we conducted secondary analyses on membrane properties such as elasticity, 
thermodynamics of mixing, and miscibility. Our data demonstrated that a decrease in CL 
content and extreme acyl chain remodeling impaired biophysical properties of mitochondrial-
mimicking monolayers. However, modest acyl chain remodeling did not have a significant 
impact on these properties. These findings are crucial for the better design of CL-specific, 










TABLE OF CONTENTS 
Page 
 
LIST OF FIGURES………………………………………………………..………………....vi 
 
LIST OF ABBREVIATIONS………………………………………………………....…….vii 
 
Chapter 
 I STUDY AIMS……………….....……………………………………………..1 
 
 II INTRODUCTION………….…………………………………………………3 
 
CL is a hallmark phospholipid of mitochondria with a     
unique structural and functional role…..……………………...………3 
 
   The role of CL in the pathogenesis of cardiometabolic diseases……..5 
 
Resolving a debate in the field – Is CL content or CL acyl            
chain composition the more important variable for           
mitochondrial membrane biophysical organization?.............................6 
 
 III METHODS………………………………………………………………..…..7 
 
   Materials…………………………………………..…………………..7 
 





Analysis of lipid miscibility, elasticity modulus, and Gibbs              




 IV RESULTS……………………………………………………………………10 
 
Monolayers of differing (18:2)4CL concentration in    
mitochondrial-mimicking phospholipid mixtures…………….……...10 
 
Monolayers of (18:2)4CL remodeling to (18:2)3CL in   
mitochondrial-mimicking phospholipid mixtures……………………12 
 
Monolayers of (18:2)4CL remodeling to (14:0)4CL in   
mitochondrial-mimicking phospholipid mixtures……………………16 
 
 V DISCUSSION………………………………………………………………..19 
 
Biological consequences for lowering (18:2)4CL content in  
 mitochondrial-mimicking monolayer studies………………………..19 
 
Mitochondrial biophysical properties are impacted by the  
 remodeling of (18:2)4CL to (14:0)4CL, but not (18:2)3CL…………..20 
 










LIST OF FIGURES 
Figure                     Page 
1. Raw isotherms for loss of CL content and resulting secondary analyses………………....11 
2.  Raw isotherms for differing concentrations of (18:2)3CL……………………………......13 
3.  Secondary analyses for differing concentrations of (18:2)3CL…………………………...15 
4.  Raw isotherms for differing concentrations of (14:0)4CL………………………………..16 




















LIST OF ABBREVIATIONS 
(14:0)4CL   tetramyristoyl cardiolipin 
(18:2)3CL   trilinoleoyl cardiolipin 
(18:2)4CL   tetralinoleoyl cardiolipin 
CL    cardiolipin 
IMM    inner mitochondrial membrane 




















Cardiolipin (CL) is a polyunsaturated phospholipid that is predominantly localized to 
the inner mitochondrial membrane (IMM), where it is synthesized and plays a fundamental 
role in maintaining inner membrane structure-function. However, in several metabolic 
diseases, in which mitochondrial dysfunction contributes towards pathology, CL’s profile is 
susceptible to considerable alterations. Two well-known alterations to CL’s profile include a 
decrease in CL content and an increase in CL acyl chain remodeling. While many studies have 
shown that these alterations contribute to mitochondrial dysfunction, there is debate in the field 
currently as to which is the major contributor to progression of disease. Therefore, the goal of 
this project is to conduct biophysical studies aimed at better understanding how alterations in 
CL concentration and CL acyl chain remodeling impair IMM biophysical organization. Results 
from this study will help to discriminate between the impact of well-known alterations to CL 
during pathology, which will allow for the better design of CL-targeted therapeutics for 
metabolic disorders. 
Our study will focus on how alterations in CL content and acyl chain composition 
impact the mitochondrial inner membrane biophysical organization. To accomplish this goal, 
we will utilize Langmuir monolayers to study how these changes impact lipid dynamics.  
 
Aim 1: Determine the impact of changes in CL content on various biophysical properties of 




in various metabolic disorders, will impact the lateral organization and thereby packing of 
adjacent lipids. 
Aim 2: Determine the impact of changes in CL acyl chain composition on various biophysical 
properties of mitochondrial-mimicking monolayers. It is hypothesized that aberrant CL acyl 
chain remodeling, as seen in various metabolic disorders, will impact various biophysical 

























Mitochondria are double-membraned organelles that are critical for many cellular 
processes including fatty acid oxidation, calcium homeostasis, as well as ATP production, and 
apoptosis (1, 2). Within mitochondria, the inner membrane is the active site for cellular 
respiration and thereby ATP production. Thus, mitochondrial structure is intimately associated 
with optimal function, which is tightly regulated by the supply of membrane constituents such 
as proteins and phospholipids. For instance, phospholipids are not only important for 
maintaining the structural integrity of cell membranes, but they are also critical for the 
compartmentalization of subcellular organelles. The major classes of phospholipids within 
mitochondrial membranes are similar to other membranes, such as the plasma membrane, and 
contain large amounts of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) (3). 
However, within the inner mitochondrial membrane, a highly unique phospholipid known as 
cardiolipin (CL) exists. Studies have shown the importance of cardiolipin for mitochondrial 
structure-function throughout a range of disease (1, 4-12). 
2.1 CL is a hallmark phospholipid of mitochondria with a unique structural and 
functional role 
CL is a highly-curved, anionic phospholipid consisting of two phosphatidic acid groups 
linked to a central glycerol molecule. CL is found almost exclusively located within the inner 
mitochondrial membrane (IMM), where it is synthesized (13). While most other phospholipids 




acyl side chains connected to two glycerophosphate backbones. The acyl chain composition of 
CL is very diverse, both among species of organisms and among different cells of the same 
organism (1, 4, 14). However, in healthy mammalian heart tissue, CL predominately adopts an 
acyl chain composition in which all four acyl chains are occupied by linoleic acid. This 
structure occupies nearly 80% of the total CL pool within the IMM (14, 15). 
CL is a major component of the IMM, occupying nearly 20% of the IMM 
phospholipidome. The importance of CL within the IMM arises from its unique structure 
which allows it to associate with many different proteins. As a result CL regulates many 
properties of mitochondrial structure-function such as bioenergetics, cristae morphology, 
respiratory enzymatic activity, cellular signaling, and apoptosis (13, 16-19). Further, CL has a 
distinct ability to interact with respiratory chain complexes and protein carriers within the 
IMM, which results from its highly unique structure and ability to form non-bilayer phases 
(20-27). For example, it has been shown that complex IV requires CL to maintain enzymatic 
function, which is compromised upon associating with remodeled forms of CL such as 
monolyso-CL (MLCL) (1, 28). In addition, CL is integral in the optimal functioning of 
cytochrome c, a membrane-associated protein necessary for the electron transfer between 
complexes III and IV. However, peroxidation of CL releases cytochrome c from the 
mitochondria to the cytosol, which initiates cellular apoptosis (29). 
Another important property of CL is its ability to form localized membrane domains. 
This property was first discovered in E. coli, where CL was observed to concentrated near the 
polar regions of the cytoplasmic membrane (30). Given CL’s unique ability to promote 




important for regulating the structure of highly-curved cristae and thereby protein function (13, 
20, 21, 31-33). 
2.2 The role of CL in the pathogenesis of cardiometabolic diseases 
CL is critical for maintaining the integrity and functionality of the IMM. However, due 
to CL’s unsaturated nature, and its close association with electron channeling, CL is susceptible 
to considerable damage (34, 35). Abnormalities in CL metabolism are causative factors in a 
variety of diseases, such as Barth Syndrome, and other cardiometabolic pathologies such as 
diabetes and cardiovascular diseases (9-11, 36). This further underscores the importance of CL 
in health and disease.  
Three well-known alterations to CL include: decreased CL content, acyl chain 
remodeling, and CL peroxidation (4, 12, 13). Here, we discuss the role of CL content versus 
CL acyl chain composition. Decreased CL content can occur from increased phospholipase 
activity, leading to CL degradation, or from decreased cardiolipin synthase activity, leading to 
decreased CL synthesis (4, 37). CL acyl chain remodeling can occur from lack of (18:2)4CL 
availability or alterations to proteins involved in CL remodeling, such as tafazzin (12). Various 
diseases manifest from these alterations in CL content and composition. For example, Barth 
syndrome and heart failure are both associated with a loss of CL content, specifically 
(18:2)4CL, whereas ischemia-reperfusion is associated with a loss of CL content and an 
increase in oxidized CL (4, 38-40). 
Mutations in tafazzin lead to a lethal and rare cardiomyopathy known as Barth 
Syndrome, characterized by decreased (18:2)4CL and increased levels of MLCL (8, 41-44). 




from degradation due to its association with IMM proteins and respiratory chain enzymes. 
However, with deficiency of tafazzin in Barth Syndrome, this protection is compromised, 
leading to unstable CL and increased CL turnover. Xu et al. discovered that tafazzin mutation 
specifically shortens the half-life of CL, which in turn leads to the accumulation of MLCL seen 
in Barth Syndrome subjects (45).  
2.3 Resolving a debate in the field – Is CL content or CL acyl chain composition the more 
important variable for mitochondrial membrane biophysical organization? 
There is debate in the field as to whether CL content versus acyl chain composition 
contributes more or less towards the progression of mitochondrial dysfunction and disease. 
Therefore, it is necessary to clearly delineate the role of such CL abnormalities and 
discriminate between their influence on inner mitochondrial lipid molecular organization. The 
goal of this study is to examine how CL concentration and CL acyl chain remodeling impact 
various biophysical properties of mitochondrial membranes. This approach utilizes biomimetic 
mitochondrial phospholipids monolayers, which allow for tight control of phospholipid 
composition. It is hypothesized that both lowered CL concentration and products of CL 
remodeling, such as MLCL, will impact the lateral organization and packing abilities of 
biomimetic mitochondrial phospholipid monolayers. 
The overall significance of this study is that we will resolve a central discrepancy in 
the field by discriminating between the impact of CL content and CL acyl chain composition 
on mitochondrial membrane properties and biophysical organization. Better understanding this 
mechanistic underpinning will allow for the design of CL-specific mitochondrial-targeted 






MATERIALS AND METHODS 
 
The following materials and methods were adapted from Pennington et al. (2017) (13). 
3.1 Materials 
The following materials were used to construct monolayers: 1-stearoyl-2-
docosahexaenoyl-sn-glycero-3-phosphocholine (18:0 -22:6 PC), 1-palmitoyl-2-arachidonoyl-
sn-glycero-3-phosphoethanolamine (16:0 -20:4 PE), 1,2-dioleoyl-sn-glycero-3-phospho-L-
serine (DOPS), 1,2-dioleoly-sn-glycero-3-phospho-(1’-myo-inositol) (DOPI), bovine heart 
cardiolipin [(18:2)4CL)], bovine heart monolyso-cardiolipin [(18:2)3CL], 1,1',2,2'-
tetramyristoyl cardiolipin [(14:0)4CL)] and cholesterol (Chol) were purchased from Avanti 
Polar Lipids (Alabaster, AL). All other reagents and solvents (HPLC grade) were purchased 
from Sigma-Aldrich (St. Louis, MO) or Fisher Scientific (Hampton, NH). All lipid mixtures 
were prepared under low light conditions and utilized fresh lipid stocks to minimize lipid 
oxidation. 
3.2 Constructing biomimetic mitochondrial monolayers 
Biomimetic mitochondrial monolayers of varying composition were synthesized by 
premixing lipid stocks in HPLC grade chloroform at the following ratios: 40 mol% 18:0-22:6 
PC, 30 mol% 16:0-20:4 PE, 20 mol% (18:2)4CL, 5 mol% DOPI, 3 mol% DOPS, and 2 mol% 
Chol. For select experiments in which CL’s acyl chain composition was altered, (18:2)4CL was 
replaced with (18:2)3CL or (14:0)4CL in a ratiometric manner. For select experiments in which 




Pressure-area isotherms were created on a Mini Langmuir-Blodgett Trough (KSV 
NIMA, Biolin Scientific, Paramus, NJ). Isotherms were compressed at a rate of 3.0 mm/min, 
and data was recorded using a Wilhelmy plate. Prior to spotting the lipid mixtures (1.08 x 10-
9 mols total) onto the 10 mM sodium phosphate buffer subphase (pH 7.4), trough barriers were 
compressed and expanded to ensure the surface pressure remained constant (<0.3 mN/m). Raw 
isotherms were collected after 10 minutes, in order to allow for the evaporation of chloroform. 
Prior to collecting each isotherm, the trough was washed three times with 70% ethanol, Milli-
Q water, and subphase. Lipid mixtures were produced multiple times to ensure day-to-day 
reproducibility. 
3.3 Analysis of lipid miscibility, elasticity modulus, and Gibbs free energy of mixing in 
monolayers 
The ideal mean molecular area of mixed monolayers was determined at a constant 
surface pressure (π) by the following equation: 
𝐴 = 𝑋 (𝐴 ) + 𝑋 (𝐴 ) +  … 𝑋 (𝐴 )  
where 𝑋  is the mol fraction of each individual component and 𝐴  is the mean molecular area 
of each component. The excess area/molecule (𝐴 ) is a measurement of lipid miscibility and 
was determined at a given surface pressure (𝜋) with the following equation: 
𝐴 = (𝐴 … ) − (𝑋 𝐴 + 𝑋 𝐴 +  … 𝑋 𝐴 )  
where 𝑋  is the mol fraction of each component and 𝐴  is the mean molecular area of each 
component. (𝐴 … ) is the mean molecular area of the mixed monolayer at a given surface 




indicates phospholipid immiscibility. The surface pressure-area isotherms were also used to 
calculate the surface elasticity modulus (𝐶 ) using the following expression: 
𝐶 = (−𝐴)(𝑑𝜋/𝑑𝐴)  
where 𝐴 is the mean molecular area of the at a given surface pressure (𝜋). The Gibbs free 
energy of phospholipid mixing (∆𝐺 ) was calculated by the following expression: 
∆𝐺 = ∆𝐺 + ∆𝐺  
where ∆𝐺  is the excess Gibbs free energy of mixing and ∆𝐺  is the ideal Gibbs free energy 
of mixing. ∆𝐺  was calculated from pressure-area isotherms using the following expression: 
∆𝐺 = [𝐴 … − ( 𝑋 𝐴 + 𝑋 𝐴 + 𝑋 𝐴 )]𝑑𝜋 
where 𝐴  and 𝑋  represent the mean molecular area and mol fraction of each component, 
respectively, at a given surface pressure (𝜋). ∆𝐺  was calculated using the following 
expression: 
 ∆𝐺 = 𝑅𝑇(𝑋 𝑙𝑛𝑋 + 𝑋 𝑙𝑛𝑋 + 𝑋 𝑙𝑛𝑋 ) 
where 𝑅 is the ideal gas constant, 𝑇 is temperature in Kelvin, and 𝑋  is the mol fraction of each 
component. 
3.4 Statistics 
Data were analyzed using GraphPad Prism v5.0b. Data were ensured to display 
normalized distributions. Statistical significance relied on one-way ANOVA, and was 








4.1 Monolayers of differing (18:2)4CL concentration in mitochondrial-mimicking 
phospholipid mixtures 
The biophysical behavior of differing CL concentrations was studied in a 
mitochondrial-mimicking phospholipid mixture. We chose to study what happens when CL is 
lowered by 25-50%, which is observed in various cardiometabolic and some neurological 
diseases (34, 38, 46-50). We start by showing raw monolayer data, which was used to generate 
secondary analyses that report on quantitative biophysical properties, such as excess area per 
molecule, elasticity modulus, and the Gibbs free energy of lipid mixing.  
We first start by presenting results in which CL concentration was manipulated in 
mitochondrial-mimicking monolayers. At a physiologically relevant surface pressure of 30 
mN/m (51, 52), lowering the level of CL in the mixture decreased the mean molecular area 
between lipid molecules, indicating a tighter packing of lipids (Figure 1A). Here, a partial loss 
of CL indicates a 25% loss of CL, whereas an absolute loss of CL is represented by a 50% 
reduction in CL mass. Our results indicate that lowering CL by 25-50% decreases the mean 
molecular area of mitochondrial-mimicking monolayers, and a reduction of CL mass by 50% 






Figure 1. Pressure-area isotherms (A) were acquired at room temperature using a 10 mM sodium 
phosphate buffer (pH 7.4). Isotherms were analyzed at 30 mN/m and used to calculate excess 
area/molecule (B), Gibbs free energy of mixing (C), and elasticity modulus (D). Data are average ± 





Decreasing CL levels disrupted the mixing properties of adjacent phospholipids as 
indicated by the excess area per molecule calculations. A 25% loss of CL content relative to 
the control decreased the excess area per molecule by 3.9 Å2, while a 50% loss of CL decreased 
the excess are per molecule by 8.2 Å2. To assess the thermodynamics of phospholipid 
interactions, we quantified the Gibbs free energy of mixing. Interestingly, while a 25% loss of 
CL relative to the control increased the Gibbs free energy by 0.3 kJ/mol, a 50% loss of CL 
decreased the Gibbs free energy by 0.5 kJ/mol (Figure 1C). Finally, we measured the elasticity 
modulus, which is an indirect measure of the phospholipid monolayers ability to undergo 
curvature. While a loss of 25% CL did not impact the elasticity modulus of the monolayer, a 
loss of 50% CL increased the elasticity modulus by 2.5 mN/m, indicating a decrease in 
curvature of the monolayer.  
4.2 Monolayers of (18:2)4CL remodeling to (18:2)3CL in mitochondrial-mimicking 
phospholipid mixtures 
Lowering CL’s concentration would presumably impair the lipid packing properties 
given the size of CL and its ability to influence the lateral organization of phospholipid 
mixtures. However, to better understand CL’s specific role in phospholipid dynamics, we 
investigated the role of CL’s acyl chain composition on the aforementioned properties of 
biomimetic mitochondrial monolayers. To do this, we studied the behavior of differing CL 
acyl chain compositions in mitochondrial-mimicking monolayers. We chose to study what 
happens when CL is remodeled to (18:2)3CL (or MLCL), as seen in many metabolic diseases, 
such as Barth syndrome (42, 43, 53). We specifically studied how varying ratios of (18:2)4CL-
to-(18:2)3CL impacted properties of monolayers, at two different surface pressures, to better 




indicates a small step-wise increase in mean molecular area from control to 6% (18:2)3CL 
(Δ4.1 Å2), followed by a small step-wise decrease in mean molecular area from 6% (18:2)3CL 
to 16% (18:2)3CL (Δ2.6 Å2) (Figure 2). 
 
 
Figure 2. Monolayers containing differing concentrations of (18:2)3CL. Pressure-area isotherms were 
conducted at ratiometric concentrations of (18:2)4CL to (18:2)3CL, totaling 20% of the total 
phospholipid mixture. Isotherms were acquired at room temperature using a 10 mM sodium phosphate 
buffer (pH 7.4). Data are average ± SEM from 6 to 8 independent experiments. 
 
 
The aforementioned raw pressure-area isotherms (Figure 2) were used to calculate the 
excess area/molecule, the Gibbs free energy of mixing (ΔGmix), and the elasticity modulus 




low and high surface pressures of 15 mN/m and 30 mN/m, the latter of which is the 
physiologically relevant surface pressure of cell membranes (51, 52). 
As the amount of (18:2)3CL increased to 6%, the excess area per molecule values 
increased relative to control, followed by a decrease in excess area per molecule values from 
6% (18:2)3CL to 16% (18:2)3CL, relative to control (Figure 3B). These changes implicate that 
increasing levels of (18:2)3CL differentially impact the lipid miscibility of mitochondrial-
mimicking monolayers, which is discussed below in detail.  Ironically, extreme levels of 
(18:2)3CL yielded the smallest increase in excess area per molecule, as compared to the control 
(Δ0.7 Å2). At 6% (18:2)3CL, the Gibbs free energy of mixing increased the greatest (Δ0.3 
kJ/mol) relative to the control, while the largest decrease in Gibbs free energy occurred at 4% 
(18:2)3CL (Δ0.5 kJ/mol) (Figure 3D). When 6% (18:2)3CL and 16% (18:2)3CL were 
incorporated into mitochondrial-mimicking monolayers, it resulted in unfavorable mixing 
values relative to the control. The elasticity modulus increased in a step-wise manner as CL 
alteration increased from control to 12% (18:2)3CL (Δ20.0 mN/m). However, at 16% 
(18:2)3CL, the elasticity modulus decreased, relative to 12% (18:2)3CL (Δ6.2 mN/m) (Figure 
3F). Similar results were observed when the monolayer was less compressed at 15 mN/m 










Figure 3. Secondary analyses of monolayers containing differing concentrations of (18:2)3CL, 
conducted at a low surface pressure of 15 mN/m (A, C, E) and a physiologically relevant surface 
pressure of 30 mN/m (B, D, F). Raw isotherms (Figure 2) were used to calculate excess area/molecule, 
Gibbs free energy of mixing, and elasticity modulus. Data are average ± SEM from 6 to 8 independent 







4.3 Monolayers of (18:2)4CL remodeling to (14:0)4CL in mitochondrial-mimicking 
phospholipid mixtures 
Finally, we studied the behavior of CL remodeling to (14:0)4CL in a mitochondrial-
mimicking phospholipid mixture. While this CL composition is not biologically relevant in 
humans, it represents a major remodeling event in which all four acyl chains are altered from 
linoleic acid to myristic acid. This alteration was also completed in a ratiometric manner to 
determine the impact of varying levels of extreme CL remodeling. Our raw isotherm data 
indicates a significant step-wise increase in mean molecular area from control to 16% 
(14:0)4CL (Δ21.3 Å2) (Figure 4). 
 
 
Figure 4. Monolayers containing differing concentrations of (14:0)4CL. Pressure-area isotherms were 
conducted at ratiometric concentrations of (18:2)4CL to (14:0)4CL, totaling 20% of the total 
phospholipid mixture. Isotherms were acquired at room temperature using a 10 mM sodium phosphate 




While the incorporation of increasing levels of (18:2)3CL had modest effects on 
membrane biophysical properties, the incorporation of (14:0)4CL leads to drastic impairments 
in the organization of mitochondrial-mimicking membranes, relative to control. Excess area 
per molecule measurements indicated a significant decrease in miscibility as (14:0)4CL was 
increased to 16% (14:0)4CL (Δ29.1 Å2) (Figure 5B). The Gibbs free energy of mixing also 
increased as the level of (14:0)4CL increased from control to 16% (Δ1.0 kJ/mol). However, at 
6% (14:0)4CL, the change in Gibbs free energy was negligible relative to control (Δ0.1 kJ/mol). 
All levels of CL alteration yielded a larger Gibbs free energy value, and therefore less favorable 
lipid mixing (Figure 5D). Finally, the elasticity modulus was significantly increased as 
(14:0)4CL levels increased from control to 16% (14:0)4CL (Δ25.7 mN/m) (Figure 5F). Nearly 















Figure 5. Secondary analyses of monolayers containing differing concentrations of (14:0)4CL, 
conducted at a low surface pressure of 15 mN/m (A, C, E) and a physiologically relevant surface 
pressure of 30 mN/m (B, D, F). Raw isotherms (Figure 4) were used to calculate excess 
area/molecule, Gibbs free energy of mixing, and elasticity modulus. Data are average ± SEM from 6 
to 8 independent experiments. * = p-value of <0.05, ** = p-value of <0.005, *** = p-value of 











5.1. Biological consequences for lowering (18:2)4CL content in mitochondrial-mimicking 
monolayer studies 
In many diseases, CL undergoes alterations in content and acyl chain composition. For 
example, a loss of CL content occurs in ischemia-reperfusion, whereas various changes occur 
to acyl chain composition in Barth Syndrome (38-40). It is suggested that these changes to CL 
would impact biophysical properties of the IMM, thereby impacting the proper functioning of 
the mitochondria. For this reason, we explored the impact of both CL content and acyl chain 
composition on mitochondrial-mimicking monolayers. 
A loss of CL content was found to decrease the mean molecular area between adjacent 
lipid molecules in our mitochondrial-mimicking monolayers. This finding suggests that 
lowered CL content, as seen in many diseases, results in a tighter packing of lipids. This has 
implications for the stability of specific lipid-protein interactions in the IMM which may 
impact mitochondrial bioenergetics and thereby ATP production. The excess area per 
molecule, an inverse measure of lipid miscibility, was found to decrease as CL content was 
lost from the sample. This finding indicates that a loss of CL results in increased mixing of 
lipids on the monolayer, which is important because CL may act as a platform for proteins to 
function optimally in microdomains. A loss of CL content therefore likely has implications for 
IMM proteins that exist and function in these domains. The elasticity modulus measures the 




the monolayer. Our findings suggest that a loss of CL content leads to an increase in the 
elasticity modulus, indicating a decrease in monolayer curvature. This finding may be partially 
attributed to the fact that CL is a highly-curved phospholipid that regulates lipid microdomains 
within the IMM. These microdomains are crucial for maintaining the highly-curved structure 
of the membrane, which helps to explain why a loss of CL results in a decrease in membrane 
curvature. Failure to maintain the highly-curved structure of the IMM may have important 
implications for the optimal functioning of respiratory chain enzymes and protein carriers of 
the IMM. 
5.2 Mitochondrial biophysical properties are impacted by the remodeling of (18:2)4CL to 
(14:0)4CL, but not (18:2)3CL. 
We further chose to study the impact of CL remodeling events on biophysical 
properties, in the hopes of better understanding the current debate over the contributions of CL 
content versus acyl chain composition on the progression of various metabolic diseases. We 
first explored the alteration of (18:2)4CL to (18:2)3CL, a common remodeling event in diseases 
such as Barth Syndrome (54, 55). 
 Exchange of (18:2)4CL with (18:2)3CL did not strongly influence monolayer excess 
area/molecule and elasticity modulus. The only exception was with 6% (18:2)3CL, which 
displayed a significant change in miscibility and elasticity when compared to the control. 
Interestingly, higher levels of (18:2)3CL began to display properties similar to the control, most 
notably in excess area/molecule but also with the elasticity modulus. Our hypothesis for this 
phenomenon is that at a certain threshold and ratio of (18:2)4CL to (18:2)3CL, the monolayer 
begins to adopt similar biophysical properties relative to control. At higher concentrations of 




the control, indicating that (18:2)3CL behaves similarly to (18:2)4CL when these lipids are in 
near equal amounts within mitochondrial-mimicking monolayers. This finding is surprising as 
we expect alterations to (18:2)4CL will impact biophysical properties of mitochondrial-
mimicking monolayers as observed when CL content is lowered. These results clearly 
implicate that increased levels of (18:2)3CL, as seen in Barth syndrome, may not strongly 
impact the biophysical properties of the IMM and thereby the activity of proteins that require 
specific lipid microenvironments for optimal function. 
 In order to further determine the impact of CL acyl chain remodeling on biophysical 
properties of mitochondrial-mimicking membranes, we chose to study (14:0)4CL. While this 
composition is only found in some bacteria and not in mammalian mitochondria (56), and 
therefore is limited in its biological relevance, our rationale for studying (14:0)4CL was to 
explore the impact of a major remodeling event for CL. This allowed us to distinguish the 
results seen from modest remodeling of (18:2)4CL to (18:2)3CL and determine if CL acyl chain 
composition plays a role in the progression of cardiometabolic disease. 
Replacement of (18:2)4CL with (14:0)4CL significantly influenced all biophysical 
properties studied, especially at higher concentrations of (14:0)4CL. The increase in excess 
area/molecule as the ratio of (14:0)4CL to (18:2)4CL increased, demonstrating that adjacent 
phospholipids become more immiscible as more (14:0)4CL is incorporated. This is also 
demonstrated through the Gibbs free energy of mixing, which also show less favorable mixing 
interactions as more (14:0)4CL is incorporated. The only exception is the 6% (14:0)4CL, which 
displayed a negligible change in free energy relative to the control. This may be due to the fact 




The IMM requires a strong membrane potential for optimal electron shuttling and 
electron transport chain (ETC) function (57). Failure for these lipids to mix properly, due to 
the lack of (18:2)4CL, would result in abnormal CL microdomain formation. This would 
further lead to a decrease in the curvature of the membrane, as demonstrated by our findings 
in the elasticity modulus, and would allow protons to leak through the ETC channels, leading 
to a lower membrane potential and less ATP production. 
Overall, our findings suggest that extreme remodeling events of (18:2)4CL impact the 
biophysical properties of mitochondrial-mimicking monolayers, however modest remodeling 
of (18:2)4CL to species such as (18:2)3CL does not seem to majorly impair the biophysical 
properties of these monolayers. 
5.3 Implications of lowered CL content versus CL acyl chain remodeling in the context 
of health and disease 
Loss of (18:2)4CL content and aberrant acyl chain remodeling occur in many diseases, 
leading to impairment of the IMM structure and function. It is suggested that both of these 
alterations to the CL profile would impact important lipid-protein interactions in the IMM. As 
the site of oxidative phosphorylation, the IMM contains numerous respiratory chain enzymes 
and protein carriers that depend on the surrounding lipid environment for optimal functioning. 
CL specifically is a crucial lipid for the formation of respiratory chain supercomplexes, acting 
as a “glue” to hold together these protein structures (20-23, 55). Therefore, it is plausible that 





These findings are important in health as a number of pharmaceutical approaches are 
currently targeting CL in the hopes of restoring metabolic defects as observed in various 
cardiometabolic diseases (58, 59). For example, a peptide known as SS-31/Bendavia has 
shown to improve mitochondrial function in animal models, specifically in diseases such as 
cardiac ischemia-reperfusion (60, 61). Bendavia functions by selectively binding to CL via 
electrostatic interactions, promoting CL aggregation within the IMM, and thereby improving 
bioenergetics by lowering ROS (62-64). The development of pharmaceutical approaches 
targeting CL are very important for helping treat cardiometabolic defects as a result of 
mitochondrial dysfunction. 
5.4 Conclusion 
 Altogether, the results demonstrate that loss of (18:2)4CL content and extreme acyl 
chain remodeling impair biophysical properties of mitochondrial-mimicking monolayers, such 
as lipid miscibility and monolayer elasticity. However, modest acyl chain remodeling, such as 
that from (18:2)4CL to (18:2)3CL, does not impair these properties. This lays the foundation 
for future studies which can further examine the impact of CL alterations on the inner 
membrane, specifically those that incorporate protein and/or occur in bilayer settings. In the 
context of mitochondrial dysfunction, this study is an important precursor towards the design 
of CL-specific therapeutics that can target, and ameliorate, the progression of pathologies 
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